Skip to main content
Home > BioCentury on BioBusiness > Tools & Tech

Chronological Index of : Tools & Techniques

 Current Issue
  • iPS predicting toxicity

    Roche early adopter of Cellular Dynamics' iPS cell platform for tox testing

    Through early access programs with pharma customers, Cellular Dynamics is gathering data that show its iPS cells predict hepatic and cardiac toxicity better than conventional assays.

    Published on 3/26/2012
  • Unnatural Selection

    Sutro Biopharma looking to build 'biosuperiors' with new CSO, fresh VC round

    With a new CSO and an injection of venture money, Sutro is ready to pick lead indications where it can use its cell-free biochemical protein synthesis technology to quickly enter the clinic with biosuperiors.

    Published on 1/10/2011
  • Arrayed Against Early Autism

    LineaGen building autism testing business around genetic microarray platform

    LineaGen hopes to parlay its efforts to identify rare autism-linked genetic variants into a testing business built around a microarray-based diagnostic platform.

    Published on 11/1/2010
  • Advanced in situ detection

    Advanced Cell Diagnostics launches RNAscope in situ RNA assay

    Advanced Cell Diagnostics has launched a single molecule RNA detection technology it believes will provide a more sensitive level of detection than protein-based assays.

    Published on 8/23/2010
  • Celling cardiotox in a dish

    Cellular Dynamics International Inc. has overcome a technical hurdle that has until now prevented the use of stem cell technologies to …

    Published on 1/4/2010
  • Replidyne's C. difficile solution

    Replidyne Inc. last week unveiled REP3123, a MetRS inhibitor in preclinical development that the company thinks will be more effective …

    Published on 9/24/2007
  • Small PEGs

    Technology Small PEGs Over the past decade, Nektar Therapeutics' pegylation capabilities have provided a growing royalty stream via third party sales of biologics that use the technology. Now, internal products that…

    Published on 9/24/2007
  • Targeting mucosal inflammation

    Technology Targeting mucosal inflammation Biogen Idec Inc. has long been interested in the late stages of inflammation where tissue remodeling and fibrosis occur. Last week's deal with LigoCyte Pharmaceuticals Inc. …

    Published on 9/24/2007
  • Complementing MAbs

    Technology Complementing MAbs Biothera thinks its Imprime PGG beta-glucan, a soluble carbohydrate, could be combined with complement-fixing MAbs to improve their efficacy compared to the MAbs alone in some cancers.…

    Published on 9/17/2007
  • Ready, steady, glow

    Technology Ready, steady, glow Researchers at Stanford University School of Medicine have developed an advanced activity-based probe they say will allow drug companies to make faster, earlier and perhaps even …

    Published on 9/17/2007
  • Metabasis' quantum hop

    The pharmaceutical industry rarely uses free energy perturbation-based methods in computer-aided drug design because these methods have low …

    Published on 9/10/2007
  • Harnessing sodium channels

    Sodium channels are large voltage-gated transmembrane proteins that play an important role in many physiological processes by …

    Published on 8/27/2007
  • Two sides to SIRT1

    In the last few years, companies have started pursuing agonism of SIRT1 as a way of boosting the body's metabolism to treat Type II diabetes, while …

    Published on 8/27/2007
  • Dynamic dimerization

    Technology Dynamic dimerization InNexus Biotechnology Inc. chose a well-validated target, CD20, to show that its second generation, conjugated monoclonal antibodies are more potent than first generation, …

    Published on 8/13/2007
  • Dysfunction stymies HDL

    Technology Dysfunction stymies HDL Although raising HDL is a major focus for many companies generating small molecule atherosclerosis therapies, the strategy has not yet led to clinical benefit. Researchers from the…

    Published on 8/13/2007
  • Expanding the liver repertoire

    Researchers from the University of North Carolina at Chapel Hill reported in the Journal of Experimental Medicine the identification and …

    Published on 8/13/2007
  • Caspase cascade

    Technology: Apoptosis shortcut Caspase cascade By targeting procaspase-3, BioLineRx Ltd. believes BL-4030 can bypass upstream elements in the intrinsic and extrinsic apoptosis pathways. In the intrinsic pathway, the…

    Published on 7/30/2007
  • Apoptosis shortcut

    Caspase cascade Targeting proteins in the apoptotic pathway can be difficult because the pathway is often rendered nonfunctional by mutations and …

    Published on 7/30/2007
  • Early mDIC-ations

    Isis Pharmaceuticals Inc. believes it is the first to show preclinical efficacy with a novel obesity target - mitochondrial dicarboxylate carrier (mDIC…

    Published on 7/9/2007
  • Lexicon's lipid-lowering antibody

    Lexicon Pharmaceuticals Inc. published data last week showing that its antibodies against angiopoietin-like protein 4 produce …

    Published on 7/9/2007
  • Nuvelo's stealth target

    Ever since Nuvelo Inc. was formed through the merger of Hyseq Pharmaceuticals Inc. and Variagenics Inc. in 2003, the company's clinical focus has …

    Published on 6/18/2007
  • What's next for mouse reprogramming

    While a presidential veto looms for the embryonic stem cell legislation that passed the U.S. House of Representatives last week, three …

    Published on 6/11/2007
  • Signal snapshots

    Mass spectrometry-based proteomics can reveal protein-protein interactions using large sample sizes and analyzing binding relationships long after a cell …

    Published on 6/4/2007
  • Catching up to GM-CSF

    Technology Briefing Catching up to GM-CSF The first hint that blocking GM-CSF might be useful to treat immune system diseases occurred about 15 years ago, when administration of the protein to treat neutropenia in …

    Published on 5/28/2007
  • Dutch imaging combine

    Technology Briefing Dutch imaging combine Diagnosing psychiatric disorders is difficult owing to poor understanding of the exact causes and mechanisms underlying them. This not only leads to problematic diagnoses, …

    Published on 5/28/2007

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993